Berzosertib (M6620, VX-970)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Berzosertib (M6620, VX-970), covering 2026-03-24 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer [Phase 1, Phase 2]